Worldwide Healthcare Trust PLC Edison issues review on Worldwide Healthcare Trust
June 12 2019 - 8:01AM
RNS Non-Regulatory
TIDMWWH
Worldwide Healthcare Trust PLC
12 June 2019
London, UK, 12 June 2019
Edison issues review on Worldwide Healthcare Trust (WWH)
Worldwide Healthcare Trust (WWH) is managed by Sven Borho and
Trevor Polischuk at OrbiMed, a major global specialist healthcare
investor. They remain constructive on the outlook for the sector,
citing strong industry fundamentals, including a 'golden era' of
innovation, a favourable regulatory environment and undemanding
company valuations. There is also the potential for further
industry mergers and acquisitions, which should be supportive for
the sector's performance. While WWH suffered a tough period of
performance in H218, it maintains a very strong long-term record;
over the last five and 10 years, it has generated NAV and share
price total returns between 14.6% and 19.2% pa and has outperformed
its benchmark over these periods in both NAV and share price
terms.
WWH's shares regularly trade close to NAV. Its current 1.4%
share price premium to cum-income NAV compares with a 0.6% average
premium over the last 12 months and average discounts of 0.9%, 2.5%
and 4.7% over the last three, five and 10 years respectively.
Although WWH aims to generate long-term capital growth, it also
offers a 1.0% dividend yield. Gearing of up to 20% of NAV is
permitted (net gearing of 7.4% at end-April 2019).
Click here to view the full report.
All reports published by Edison are available to download free
of charge from its website
www.edisongroup.com
About Edison: Edison is an investment research and advisory
company, with offices in North America, Europe, the Middle East and
AsiaPac. The heart of Edison is our world-renowned equity research
platform and deep multi-sector expertise. At Edison Investment
Research, our research is widely read by international investors,
advisers and stakeholders. Edison Advisors leverages our core
research platform to provide differentiated services including
investor relations and strategic consulting.
Edison is authorised and regulated by the Financial Conduct
Authority.
Edison is not an adviser or broker-dealer and does not provide
investment advice. Edison's reports are not solicitations to buy or
sell any securities.
For more information please contact Edison:
Mel Jenner, +44 (0)20 3077 5720
Sarah Godfrey, +44 (0)20 3681 2519
investmenttrusts@edisongroup.com
Learn more at www.edisongroup.com and connect with Edison
on:
LinkedIn https://www.linkedin.com/company/edison-investment-research
Twitter www.twitter.com/Edison_Inv_Res
YouTube www.youtube.com/edisonitv
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAFTMBTMBABBRL
(END) Dow Jones Newswires
June 12, 2019 08:01 ET (12:01 GMT)
Finsbury Worldwide Pharm (LSE:FWP)
Historical Stock Chart
From Oct 2024 to Nov 2024
Finsbury Worldwide Pharm (LSE:FWP)
Historical Stock Chart
From Nov 2023 to Nov 2024